Search results
Results from the WOW.Com Content Network
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
In 2021, the FDA granted pre-market approval to the Impella RP with SmartAssist, a first single-access, dual-sensor technology device to provide temporary percutaneous ventricular support for patients with acute right heart failure or decompensation after implanting a left ventricular assist device, myocardial infarction, heart transplant or ...
The association collaborates with the Canadian Foundation for Infectious Diseases in raising money to support infectious diseases research in support of its mission. [13] Corporate partners of the CFID include AbbVie, BD, BioMérieux, Gilead Sciences, KPMG, Merck, and Sunovion. [14]
The PAN Foundation operates financial assistance, advocacy, and education initiatives to help accelerate access to care for those who need it most. Through its more than 80 disease-specific financial assistance programs, PAN serves well over 100,000 patients each year from every US state and territory. [ 4 ]
Expanded access or compassionate use is the use of an unapproved drug or medical device under special forms of investigational new drug applications (IND) or IDE application for devices, outside of a clinical trial, by people with serious or life-threatening conditions who do not meet the enrollment criteria for the clinical trial in progress.
Image source: The Motley Fool. Johnson & Johnson (NYSE: JNJ) Q4 2024 Earnings Call Jan 22, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
The Partnership for Prescription Assistance is a program by PhRMA and its member companies that connects patients in-need with information on low-cost and free prescription medication. [24] PhRMA has in 2017 raised concerns over price increases for generic drugs out of patent by the company Marathon Pharmaceuticals over Duchenne muscular ...
In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen. [154]